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Canine leishmaniasis (CanL) in Mediterranean coun-
tries is a protozoan disease caused by Leishmania
infantum. This disease can be caused not only by
L. infantum. Several different Leishmania species are
described (24).
CanL occurs also in South and Central America, East
and North Africa, and South Asia. Epidemiological
studies indicate that CanL has become an emerging
problem in some dog breeds in the USA and Canada
(6). Since dogs are the main reservoirs of the parasite,
a decreased incidence of CanL in this animal species
seems to be related to the control of infection. Dogs
culling fails to reduce the transmission of the parasite
and should be abandoned as a control measure, for
ethical considerations, also (5). The treatment of
individual pet dogs is intensively practiced in Europe
and it is proven to reduce clinical disease, parasite load,
and infectivity to sandflies (17). Together with the
administration of anti feeding and insecticide drugs,
the treatment represents a milestone of the control.
Currently available therapeutic options are limited,
and first choice drug is the combined treatment with
meglumine antimoniate (a pentavalent antimonial), and
allopurinol. Sodium stibogluconate is a further penta-
valent antimonial available in anglo-saxon countries.
Unfortunately, treatment does not prevent relapse of
disease, so there is a search for effective and safe anti-
-Leishmania drugs. Other compounds used to treat
such infection comprehend aminosidine, miltefosine,
amphotericin B (1) and different quinolones (3, 19).
WHO recommends to avoid to use miltefosine, paro-
momycine and amphotericin B for dogs (2) given that
they can induce parasite resistance (11, 16), although
miltefosine has been licensed since 2007 in Europe
for veterinary use and has been extensively used. The
data available from literature report conflicting results
about the efficacy of miltefosine in dogs (13, 15, 23).
Similarly, among quinolones marbofloxacin has suc-
cessfully been employed in vitro against L. infantum
(8) and in vivo (19), while enrofloxacin was proven to
be poorly effective (3).
The aim of the present paper was to evaluate the
anti-Leishmania activity of 3 different protocols of
treatment on dogs naturally infected by L. infantum,
during a 24-months parasitological and clinical fol-
low-up.
Material and methods
Forty-two client owned dogs diagnosed with canine
leishmaniasis were included in the study. The animals were
of different breed, both genders, and aged from 1 to 13
years (mean 6, median 5).
Inclusion criteria were: an indirect immunofluorescence
antibody test (IFAT) titre ‡ 80, positive polymerase chain
reaction (PCR) from blood, lymph-node and conjunctiva,
the presence of at least one clinical sign of canine leish-
maniasis (lymphadenopathy, weight loss, skin lesions,
muscular atrophy, pale mucous membranes, articular pain,
onychogryphosis, conjunctivitis) at the moment of diagno-
sis together with the fulfilling criteria for stage II or III
according to Solano-Gallego et al., (2009) (20). Dogs with
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severe renal failure, (uraemia ‡ 1 g/l, creatininaemia > 20
mg/l), positive serology to Ehrlichia canis ‡ 1 : 200, already
treated for CanL and without informed consent from the
owner were excluded from the trial. Thirty-two animals
fulfilled the criteria for stage II, the others were rated as
stage III. IFAT titres were ranging from 80 to 5120.
IFAT was carried out as described elsewhere (12)
starting from 1/80 dilution until to extinction value. A PCR
for Leishmania DNA detection was carried out on blood
samples, lymph-node biopsy and conjunctival swabs. DNA
was extracted from tissues with a DNA purification kit
(Wizardfi Genomic, Promega), according to the manu-
facturers protocol. PCR for Leishmania sp. was performed
as previously described (18).
A complete physical examination as well as complete
blood count (CBC), biochemical profile and urinalysis,
including protein/creatinine ratio, were performed on all the
animals at day 0. A complete clinical and parasitological
examination was carried out at days 90, 180, 360 and 720.
Dogs were randomly assigned to three different treat-
ment regimen groups. Fourteen dogs were administered
per os miltefosine (Milteforanfi, Virbac) 2 mg/kg SID plus
allopurinol (Zyloricfi Glaxo, Wellcome) 10 mg/kg BID, for
30 days and for 1 year, respectively (group A). Further 13
animals were given per os difloxacin cloridrate (Dicuralfi,
Fort Dodge Animal Health) 5 mg/kg plus metronidazole
(Flagylfi, Zambon Italia) 25 mg/kg for 30 days. The other
dogs (n = 15) were treated with meglumine antimoniate
(Glucantimefi, Merial Italia, SRL) at a dose of 100 mg/kg
BID subcutaneously plus allopurinol (Zyloricfi Glaxo,
Wellcome) 10 mg/kg BID per os, for 30 days and for
1 year, respectively. A further course of each treatment was
administered at day 360, to the subjects showing at least
a parasitological positivity. All the enrolled subjects had
a normal renal function, 9 and 10 animals showed anemia
from groups A and B, respectively, as well as 7 dogs from
group C, while A/G ratio was impaired in 7 dogs from
group A, 6 from group B and 10 from group C.
Results and discussion
After the beginning of each treatment a progressive
improvement of clinical signs was observed in all
animals. At day 720 anemia was normalized in 5/9
dogs from group A, 4/10 from group B and 6/7 from
group C, respectively, while A/G ratio was improved
in 5/7 and 5/6 subjects from groups A and B, and in
9/10 dogs from group C. Adverse effects were never
noticed.
Data regarding parasitological parameters showed
a general decrease of IFAT titres, at day 720, while
7 animals maintained the initial value (3 from group A,
1 from group B and 3 from group C). One dog from
group C registered an increase of the titre (from 320 to
640) with positive PCR results on all examined tissues.
Three animals from group B resulted negative both to
serologic and molecular determinations (2 animals
since day 90, the other after a further course of treat-
ment). One dog from group C scored negative to all
parasitological tests at day 180, 1 at day 360, and
the other 3 subjects showed negative parasitological
Explanations: * at day 0, all tissues scored positive to PCR assay;
** blood; *** conjunctiva; **** lymph node
Tab. 1. Serological and molecular data of examined animals
at days 0 and 720 after the beginning of the treatments
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results after the further course of treatment. Further-
more 3 subjects from group A, 4 from group B and
7 from group C yielded PCR negative results in at least
1 examined tissue at day 360. All parasitologically
negative subjects did not relapse. All these subjects
became clinically asymptomatic. More detailed results
are reported in Tab. 1.
The results of the present study show that miltefosine
did not allow any treated dog to become negative to
both clinical and parasitological tests. This finding
agrees with data reported by Manna et al. (2009) (13),
who detected residual parasite load after administra-
tion of this drug. Three out of 13 animals treated with
difloxacin and 5 out of 15 subjects treated with
meglumine antimoniate plus allopurinol underwent
to both clinical and parasitological cure at day 720.
Difloxacin was never employed in the treatment
of CanL; this treatment allowed a faster clinical and
parasitological recovery. Previous in vitro studies
demonstrated a direct and indirect leishmanicidal
activity of marbofloxacin via the TNF-a and NO syn-
thase pathways, and correlated with NO
2
 production
(22), while enrofloxacin, has recently been tested as
a single treatment in leishmaniosis but without any
significant results (3). Difloxacine seems to promote
a good response in affected dogs. The different treat-
ments used in this study did not completely eliminate
the parasite, but the use of meglumine antimoniate and
allopurinol would improve dogs clinical condition and
reduce or eliminate the parasite from the skin signifi-
cantly reduces the infectivity of reservoir towards
sandflies, decreasing the epidemiological risk (10, 14).
The risk of induce the selection of drug-resistant
parasites after pharmacological pressure is reported in
literature. Cases of resistance to antimonials, both in
vitro and in vivo are reported (7, 9). Parasite resistance
to miltefosine can be induced experimentally, and the
long half-life of this drug in vivo makes it vulnerable
to the development of resistance in endemic regions
(21). Furthermore a possible marker of miltefosine
resistance in leishmaniasis has been identified (4).
To the best of our knowledge resistance was never
claimed with quinolones, when administered against
this parasite.
Our results suggest that, apart from miltefosine, the
other two therapeutic regimens could be evaluated to
treat animals with CanL in medium-endemicity area.
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